Agenus (NASDAQ: AGEN) and ImmunoGen (NASDAQ:IMGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.

Earnings and Valuation

This table compares Agenus and ImmunoGen’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Agenus $41.19 million 8.98 -$92.05 million ($1.27) -2.92
ImmunoGen $83.41 million 6.94 -$69.45 million ($1.20) -5.38

ImmunoGen has higher revenue and earnings than Agenus. ImmunoGen is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Agenus and ImmunoGen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Agenus -280.96% -37,577.49% -65.05%
ImmunoGen -117.80% N/A -52.58%

Insider & Institutional Ownership

39.5% of Agenus shares are held by institutional investors. Comparatively, 84.6% of ImmunoGen shares are held by institutional investors. 7.9% of Agenus shares are held by insiders. Comparatively, 6.5% of ImmunoGen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Agenus has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Comparatively, ImmunoGen has a beta of 2.42, indicating that its stock price is 142% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Agenus and ImmunoGen, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agenus 0 1 3 0 2.75
ImmunoGen 1 2 5 0 2.50

Agenus currently has a consensus target price of $6.33, suggesting a potential upside of 70.71%. ImmunoGen has a consensus target price of $7.72, suggesting a potential upside of 19.45%. Given Agenus’ stronger consensus rating and higher possible upside, research analysts plainly believe Agenus is more favorable than ImmunoGen.

Summary

ImmunoGen beats Agenus on 9 of the 13 factors compared between the two stocks.

About Agenus

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company’s discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company’s vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

About ImmunoGen

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.